Imugene Ltd (ASX:IMU) has appointed leading global pharmaceutical executive Dr. Lesley Russell as a non-executive director, effective April 23, 2019.
Dr. Russell has more than 25 years of international operational and leadership experience with a number of established and emerging pharmaceutical companies across multiple therapeutic areas including oncology and haematology.
READ: Imugene well-funded to progress clinical milestones
Her experience has been gained at a number of leading companies including Amgen (NASDAQ:AMGN), Eli Lilly (NASDAQ:LLY), Cephalon Inc (NASDAQ:CEPH) and Teva Pharmacaeuticals (NASDAQ:TEVA).
Dr. Russell is currently a non-executive director of AMAG Pharmaceuticals (NASDAQ:AMAG), Enanta Pharmaceuticals (NASDAQ:ENTA) and Sojournix a privately held biotechnology company.
READ: Imugene presents positive new data validating its human cancer vaccine KEY-Vaxx
Imugene executive chairman Paul Hopper said: “Dr. Lesley Russell’s global industry knowledge and direct experience of oncology drug development and strategic joint ventures will further enhance the board’s skill mix.
“We are delighted she is joining our business and look forward to her contributions as we work to advance our promising cancer vaccine pipeline.”